The Daughters of the American Revolution Membership Integrity Act amends federal law to explicitly define membership eligibility for the organization. It requires that members be women, legally defined as adult human females who possess a reproductive system capable of producing ova for fertilization. This provision clarifies the genealogical and biological qualifications needed to join the group while maintaining its existing membership structure.
The Making America's Food Safer Act expands the FDA's existing third-party certification program to allow more entities in the food supply chain to use independent audits for importing food into the United States. It also updates how the FDA uses these certifications to assess food safety and prioritize inspections, while establishing a formal system to recognize the organizations that accredit these auditors. Additionally, the bill permits the FDA to share unredacted food safety data, such as illness surveillance and inspection results, with state, local, and tribal health authorities to help them protect public health. Finally, it gives the FDA the authority to order the immediate destruction of imported food that poses a significant public health risk, provided the owner receives notice and an opportunity to challenge the decision.
S 380, the Rural Obstetrics Readiness Act, creates a federal program to improve emergency obstetric care in rural health facilities without dedicated obstetric units. It establishes evidence-based training for non-obstetric providers to handle childbirth emergencies (like hemorrhage or severe hypertension), funds equipment purchases, and launches a telehealth pilot for rapid specialist consultations. The bill authorizes $5 million for training (2026-2028), $15 million for equipment and workforce support (2026-2029), and $5 million for teleconsultation (2026-2029). It directly affects rural hospitals and clinics in maternity care shortage areas, requiring them to coordinate with maternal health programs and develop emergency protocols. A separate study will map maternity ward closures and regional care patterns, reporting to Congress within three years.
The RESCUE Act of 2026 updates how the federal government reimburses ground and air ambulance services by changing the payment schedule and data collection rules. Starting in 2028, the Secretary of Health and Human Services will adjust payment rates every three years based on new data regarding costs, labor, and uncompensated care, while years in between will see payments increase only by the standard inflation rate. The bill also requires air ambulance providers to submit cost information to the government at least once every three years, aligning this process with existing rules for ground ambulance services. Additionally, the law mandates a review by 2029 to gather expert recommendations on whether further changes are needed to ensure ambulance providers are paid appropriately. These changes directly affect ambulance companies and the federal programs that fund emergency medical transport.
This Senate resolution commemorates June 19, 2026, as Juneteenth National Independence Day to honor the 1865 announcement of freedom to enslaved people in Texas and the Southwestern States. The bill serves as a formal recognition of this historical event and does not create new laws or change federal holidays. It aims to support nationwide celebrations and encourage learning about the history of slavery and emancipation in the United States.
The CLEAR LABELS Act (S 3788) requires drug manufacturers, packers, and distributors to label finished drugs and active pharmaceutical ingredients with specific supply chain information. This includes the name, location, and unique facility ID of the original manufacturer for both active ingredients and finished products, either directly on labels or via QR codes/link to an electronic portal. The bill directly affects drug companies and distributors by mandating clearer labeling to trace products through the supply chain. It also exempts compliant drugs from separate customs country-of-origin marking requirements. These changes aim to improve transparency for consumers and regulators about drug origins.
The Patients Deserve Price Tags Act requires hospitals, clinical diagnostic laboratories, imaging services providers, and ambulatory surgical centers to publicly disclose detailed pricing information for healthcare services in machine-readable formats. This includes standard charges, discounted cash prices, payer-specific negotiated rates, and other relevant pricing data that consumers can easily access and compare. The law applies to all facilities that provide services to Medicare beneficiaries, with implementation dates starting in 2026 for hospitals and 2027 for other providers. Non-compliant facilities face daily civil monetary penalties ranging from $300 to $10,000 per day, depending on facility size and duration of non-compliance.
The GRACE Act prohibits federal education funding for schools and agencies that mandate vaccinations unless they offer a specific exemption process. Under this bill, institutions must allow parents or guardians to request an exemption based on a sincerely held religious belief without requiring any supporting documentation. The law defines a child as anyone under 18 and applies these rules to elementary and secondary schools as well as local and state educational agencies. By removing the need for proof of religious belief, the measure aims to simplify the process for families seeking to opt out of vaccination requirements for religious reasons.
The PERFORM Act restricts the Postmaster General from receiving bonuses or performance-based pay if the Postal Service runs a financial deficit, misses service targets, or fails to pass its annual audit. To enforce this, the law requires the Postmaster General to submit an annual report to Congress detailing all executive compensation, the metrics used to justify those payments, and the agency's financial and service performance data. Additionally, the Postal Service Inspector General must review these reports to ensure compliance with the new restrictions. These measures directly affect the compensation of senior Postal Service leadership and increase transparency regarding the agency's financial and operational results.
The AI Transparency in Elections Act of 2026 requires political advertisements containing content substantially generated by artificial intelligence to include clear and conspicuous disclaimers. These labels must appear on images, audio, and video ads that advocate for or against candidates, solicit contributions, or refer to candidates within 120 days of an election. The bill mandates that visual disclaimers be as large as the main text, while audio disclaimers must be spoken for at least four seconds at the beginning or end of the recording. Violations of these disclosure rules could result in civil money penalties of up to $50,000 per ad, and the Federal Election Commission is tasked with creating specific regulations to enforce the law.
The WINGS Act of 2026 expands federal financial aid eligibility to cover specific aviation training expenses for students enrolled in qualifying aviation programs at colleges and universities. Under this bill, students could use federal funds to pay for costs such as flight simulator hours, aircraft instruction, aviation training materials, and licensing exam fees. The legislation defines eligible programs as those offering associate's or bachelor's degrees in aviation-related fields and includes professional degree programs that meet specific regulatory training standards. These changes would take effect on July 1, 2027, allowing students to access financial support for practical aviation training components starting with the 2027-2028 award year.
This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
